Navigation

AIMM Therapeutics AIMM Therapeutics
Home

menu-mobiel

  • Science and technology
    • Core technology
    • Discover
      • Human
      • Animal
    • Improve
    • Link
    • Publications
  • Pipeline
  • Partnering
    • Active collaboration
    • Platform licensing
    • Licensing antibodies
    • Academic collaboration
  • About us
    • Management
      • CEO John Womelsdorf
      • COO Willem van Oort
      • CSO Hergen Spits
    • Board of directors
      • Jan de Vries
      • Tom Schwarz
      • Donald Kalff
      • Thomas Jung
    • Scientific advisory board
      • Careers
      • Contact
  • News and events
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
Return to Content
Discovering therapeutic antibodies designed by nature
You are here: Home › News and events › 2012 › BIO-Europe Spring 2012

BIO-Europe Spring 2012

AIMM presents at the BIO-Europe Spring 2012 meeting in Amsterdam

March 13, 2012

AIMM Therapeutics presents at the BIO-Europe Spring 2012 meeting in Amsterdam.

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Related Posts:

  • Strategic partnership with Cosmo Pharmaceuticals
  • New CEO and VP Business Development
  • BIO International Convention, Boston
  • Science webinar online
  • AIMM to present at Science webinar
previous news item
next news item
AIMM Therapeutics
  • Science and technology
    • Core technology
    • Discover
      • Human
      • Animal
    • Improve
    • Link
    • Publications
  • Pipeline
  • Partnering
    • Active collaboration
    • Platform licensing
    • Licensing antibodies
    • Academic collaboration
  • About us
    • Management
      • CEO John Womelsdorf
      • COO Willem van Oort
      • CSO Hergen Spits
    • Board of directors
      • Jan de Vries
      • Tom Schwarz
      • Donald Kalff
      • Thomas Jung
    • Scientific advisory board
    • Careers
    • Contact
  • News and events
    • 2018
    • 2017
    • 2016
    • 2015
      • MEDI8897 on fast track
      • MEDI8897 into Phase Ib/IIa
    • 2014
      • Nature Medicine publication
      • PNAS publication
      • 10 year anniversary symposium
      • Medimmune
    • 2013
      • PNAS
      • Nature SciBX review
      • Pre-fusion RSV Antibodies
      • PLOS pathogens paper
      • Innovation Credit
      • ERC Advanced Grant
      • Nature webcast
      • SAB strengthened
      • D25 binding revealed
    • 2012
      • Strategic partnership
      • New CEO and VP
      • BIO International
      • Science webinar online
      • BIO-Europe Spring 2012
      • Science webinar

Bibo Design & Studio Singel